Compare GSK plc (GSK) vs Harmony Gold Mining Co. (HMY) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Harmony Gold Mining (HMY) trades at $14.84, down 2.62% amid broader gold sector weakness. The stock shows bearish technical signals with support at $14 and resistance at $16. Fundamentally, HMY delivered strong 2024 results with $61.38B revenue and $8.59B net income, though it missed Q4 2025 EPS estimates. Valuation metrics appear attractive with P/E of 9.69 and EV/EBITDA of 5.04. Recent news highlights Fed rate hike concerns impacting gold prices while some analysts point to the company's transition to gold-copper hybrid operations.

HMY presents a mixed outlook with undervalued fundamentals conflicting with near-term sector headwinds. Investment opportunity lies in its low valuation, 4.06% dividend yield, and copper expansion strategy. Key risks include gold price volatility, rising interest rates, and execution challenges in operational transition. Analyst consensus remains cautious with 70% hold ratings, suggesting waiting for clearer catalysts before establishing positions.